Premium
Trials of 9‐Amino‐20(S)‐Camptothecin in Boston
Author(s) -
EDER JOSEPH P.,
RUBIN ERIC,
STONE RICHARD,
BRYANT MARGARET,
XU GUANXIAN,
SUPKO JEFFREY,
KINCHLA NANCY,
LYNCH THOMAS,
HURWITZ SELWYN,
RODRIGUEZ DEE,
SHAPIRO CHARLES,
TOPPMEYER DEBORAH,
GROSSBARD MICHAEL,
VOSBURG EVAN,
HUBERMAN MARK,
SCHNIPPER LOWELL,
SHULMAN LAWRENCE,
KUFE DONALD W.
Publication year - 1996
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.1996.tb26394.x
Subject(s) - gerontology , medicine , classics , library science , history , computer science
9-Amino-20(S)-camptothecin (9-AC) is an analog of camptothecin with limited water solubility which has shown significant preclinical activity in a variety of human solid tumor xenografts. A Phase I trial using a soluble formulation of 9-AC, given as a 72-hour continuous infusion, has been completed. Thirty-one patients with resistant cancers received 5-60 micrograms/M2/h at three week intervals. The Maximum Tolerated Dose (MTD) was 45 micrograms/M2/hour. Neutropenia was the dose limiting toxicity, with few significant non-myelosuppressive toxicities. Minor responses were seen in 3/31 patients. Pharmacokinetic studies of 9-AC lactone (closed ring) showed substantial interpatient variability with a predicted half-life of 36 hours. A phase I/II trial of the same formulation of 9-AC is ongoing in refractory leukemia. Stomatitis and diarrhea are the non-myelosuppressive dose limiting toxicities. Evidence of antineoplastic activity has been seen in 3/15 patients. A Phase II trial in previously untreated metastatic breast cancer is also underway. A Phase I trial of a colloidal dispersion formulation, not yet completed, is better tolerated with a MTD > 45 micrograms/M2/h as a 72-hour continuous infusion. Evidence of antineoplastic activity has also been demonstrated.